KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Amortization of Deferred Charges (2019 - 2024)

Alnylam Pharmaceuticals filings provide 6 years of Amortization of Deferred Charges readings, the most recent being $13.1 million for Q3 2024.

  • Quarterly Amortization of Deferred Charges rose 27.95% to $13.1 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $45.2 million through Sep 2024, up 4.98% year-over-year, with the annual reading at $43.0 million for FY2023, 4.61% up from the prior year.
  • Amortization of Deferred Charges hit $13.1 million in Q3 2024 for Alnylam Pharmaceuticals, up from $9.7 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $13.1 million in Q3 2024 and bottomed at $9.4 million in Q1 2020.
  • Average Amortization of Deferred Charges over 5 years is $10.6 million, with a median of $10.3 million recorded in 2023.
  • The largest annual shift saw Amortization of Deferred Charges dropped 12.1% in 2022 before it rose 27.95% in 2024.
  • Alnylam Pharmaceuticals' Amortization of Deferred Charges stood at $10.5 million in 2020, then decreased by 3.98% to $10.1 million in 2021, then increased by 4.94% to $10.6 million in 2022, then dropped by 0.78% to $10.5 million in 2023, then grew by 24.45% to $13.1 million in 2024.
  • Per Business Quant, the three most recent readings for ALNY's Amortization of Deferred Charges are $13.1 million (Q3 2024), $9.7 million (Q2 2024), and $12.0 million (Q1 2024).